Regarding Q3(assuming that is 7/1--9/30 2024), that is when Amarin lost the CVS/Caremark account, losing the supply contract and formulary position to the generics like Hikma and Dr. Reddy. My insurance company, 7/1, had sold its Vascepa coverage business. I wound up paying > $1000 for a 3-month refill for Vascepa rather than the Dr. Reddy formulation then on CVS shelves. My standard DAW scrip for Vascepa from my PCP "somehow had been erased" from CVS pharmacy computer files, and I was given a Dr. Reddy product instead(3 bottles of capsules wrapped in a stapled brown paper bag). I returned 2 bottles of Dr. Reddy product, kept 1 bottle with label and encapsulated product for later use as evidence of collusive healthcare fraud.
I later refilled a new DAW scrip for Vascepa, still at a much higher comparative price than the co-pay price of $9-15 I had paid for years prior to 7/1/2024.
The physical evidence, capsules, receipts, etc., will be sent FTC Chair Ferguson and/or Attorney General this coming week, along with photocopy pages from our shareholder Petition for Writ of Certiorari in the Nevada Hikma/DRL matter, 7/1/2024 letter from insurance company, copy of CAFC opinion reversing D.Delaware judge in Hikma v. Amarin, and other evidence.
The FTC chair, even this morning when interviewed by a CNBC reporter, has made it clear he intends to use his resources to protect the American population from collusive fraud, particularly in the pharmaceutical industry. H and DRL do not belong as competitors in any aspect of Amarin's high triglycerides or CVD businesses, IMO. Their products should be banned from distribution and sale.
Market Data 
Markets 
